MX2018009496A - Degradadores selectivos del receptor de estrogeno y sus usos. - Google Patents
Degradadores selectivos del receptor de estrogeno y sus usos.Info
- Publication number
- MX2018009496A MX2018009496A MX2018009496A MX2018009496A MX2018009496A MX 2018009496 A MX2018009496 A MX 2018009496A MX 2018009496 A MX2018009496 A MX 2018009496A MX 2018009496 A MX2018009496 A MX 2018009496A MX 2018009496 A MX2018009496 A MX 2018009496A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degraders
- formula
- present disclosure
- Prior art date
Links
- 229940125641 estrogen receptor degrader Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente descripcion proporciona compuestos de formula (I) y formula (II); los compuestos descritos en este documento pueden ser utiles en el tratamiento de enfermedades proliferativas (por ejemplo, cancer); tambien se proporcionan en la presente descripción composiciones farmaceuticas, kits, metodos y usos que incluyen o utilizan un compuesto descrito en el presente documento. (VER FÓRMULAS).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291921P | 2016-02-05 | 2016-02-05 | |
PCT/US2017/016452 WO2017136688A1 (en) | 2016-02-05 | 2017-02-03 | Selective estrogen receptor degraders and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018009496A true MX2018009496A (es) | 2018-12-11 |
Family
ID=59501091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009496A MX2018009496A (es) | 2016-02-05 | 2017-02-03 | Degradadores selectivos del receptor de estrogeno y sus usos. |
Country Status (15)
Country | Link |
---|---|
US (4) | US10647724B2 (es) |
EP (1) | EP3411034B1 (es) |
JP (1) | JP6905539B2 (es) |
KR (1) | KR102479822B1 (es) |
CN (2) | CN113004273A (es) |
AU (1) | AU2017213614B2 (es) |
BR (1) | BR112018015419B1 (es) |
CA (1) | CA3012078C (es) |
DK (1) | DK3411034T3 (es) |
ES (1) | ES2842579T3 (es) |
IL (1) | IL260789B (es) |
MX (1) | MX2018009496A (es) |
RU (1) | RU2734501C2 (es) |
WO (1) | WO2017136688A1 (es) |
ZA (1) | ZA201805573B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11278532B2 (en) | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9980947B2 (en) | 2014-12-18 | 2018-05-29 | Genentech, Inc. | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
WO2017119917A1 (en) * | 2016-02-26 | 2017-07-13 | Triangle Research Labs, LLC | Method for pooling hepatocytes |
CN107428758B (zh) * | 2015-11-12 | 2020-08-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
BR112018015419B1 (pt) * | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
MX2018011419A (es) | 2016-04-01 | 2019-06-06 | Zeno Royalties & Milestones Llc | Moduladores de receptores estrogénicos. |
CN109311876B (zh) * | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
KR20200135961A (ko) | 2018-02-28 | 2020-12-04 | 페로 테라퓨틱스 인코포레이티드 | 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법 |
CN110343101B (zh) * | 2018-04-04 | 2022-07-12 | 青岛福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
UA128114C2 (uk) | 2018-06-21 | 2024-04-10 | Ф. Хоффманн-Ля Рош Аг | Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування |
AU2019321588A1 (en) | 2018-08-17 | 2021-03-04 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
MX2021007687A (es) | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
JP2022534037A (ja) * | 2019-05-24 | 2022-07-27 | 浙江海正薬業股▲ふん▼有限公司 | アクリル酸系誘導体の結晶形およびその調製方法及び用途 |
WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
WO2024042163A1 (en) * | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2473441A1 (en) | 2002-01-18 | 2003-07-24 | The Genetics Company Inc. | Beta-secretase inhibitors |
US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
WO2004091488A2 (en) * | 2003-04-14 | 2004-10-28 | Merck & Co., Inc. | Estrogen receptor modulators |
PL1737461T3 (pl) * | 2004-03-15 | 2013-05-31 | Ptc Therapeutics Inc | Pochodne karbolinowe użyteczne w hamowaniu angiogenezy |
TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
US8703726B2 (en) * | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
CA2778357A1 (en) * | 2009-10-22 | 2011-04-28 | Polymedix, Inc. | Processes for preparing a polymeric compound |
ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
TWI560172B (en) * | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
CA2857057A1 (en) * | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
US20140122109A1 (en) * | 2012-10-29 | 2014-05-01 | Consuli, Inc. | Clinical diagnosis objects interaction |
MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
EP3004090B1 (en) * | 2013-05-28 | 2017-10-25 | Astrazeneca AB | Chemical compounds |
CA2915534A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
AU2015228860A1 (en) | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
JP6690534B2 (ja) | 2014-06-12 | 2020-04-28 | 小野薬品工業株式会社 | ストレス性疾患の予防および/または治療用医薬 |
US9980947B2 (en) * | 2014-12-18 | 2018-05-29 | Genentech, Inc. | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
WO2016202161A1 (zh) | 2015-06-16 | 2016-12-22 | 江苏恒瑞医药股份有限公司 | 哌啶类衍生物、其制备方法及其在医药上的应用 |
EP3912680A1 (en) * | 2015-10-01 | 2021-11-24 | Olema Pharmaceuticals, Inc. | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
CN107428758B (zh) * | 2015-11-12 | 2020-08-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
BR112018015419B1 (pt) * | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
MX2018011419A (es) | 2016-04-01 | 2019-06-06 | Zeno Royalties & Milestones Llc | Moduladores de receptores estrogénicos. |
CN109311876B (zh) | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
WO2017216280A1 (en) | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
US10774081B2 (en) | 2016-10-28 | 2020-09-15 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Indolo substituted piperidine compound as estrogen receptor down-regulator |
WO2018130124A1 (zh) | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
JOP20190183B1 (ar) | 2017-01-30 | 2022-09-15 | Astrazeneca Ab | معدِلات مستقبلات الاستروجين |
MX2021007687A (es) * | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
-
2017
- 2017-02-03 BR BR112018015419-9A patent/BR112018015419B1/pt active IP Right Grant
- 2017-02-03 DK DK17748247.8T patent/DK3411034T3/da active
- 2017-02-03 CA CA3012078A patent/CA3012078C/en active Active
- 2017-02-03 MX MX2018009496A patent/MX2018009496A/es unknown
- 2017-02-03 CN CN202110236070.7A patent/CN113004273A/zh active Pending
- 2017-02-03 JP JP2018560447A patent/JP6905539B2/ja active Active
- 2017-02-03 US US16/073,673 patent/US10647724B2/en active Active
- 2017-02-03 KR KR1020187025594A patent/KR102479822B1/ko active IP Right Grant
- 2017-02-03 CN CN201780008535.5A patent/CN109362222B/zh active Active
- 2017-02-03 ES ES17748247T patent/ES2842579T3/es active Active
- 2017-02-03 EP EP17748247.8A patent/EP3411034B1/en active Active
- 2017-02-03 AU AU2017213614A patent/AU2017213614B2/en active Active
- 2017-02-03 WO PCT/US2017/016452 patent/WO2017136688A1/en active Application Filing
- 2017-02-03 RU RU2018128318A patent/RU2734501C2/ru active
-
2018
- 2018-07-26 IL IL260789A patent/IL260789B/en active IP Right Grant
- 2018-08-21 ZA ZA2018/05573A patent/ZA201805573B/en unknown
-
2019
- 2019-10-17 US US16/655,689 patent/US11014936B2/en active Active
-
2021
- 2021-04-27 US US17/241,722 patent/US20210253592A1/en not_active Abandoned
-
2023
- 2023-07-11 US US18/220,484 patent/US20240043442A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11278532B2 (en) | 2019-08-06 | 2022-03-22 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
Also Published As
Publication number | Publication date |
---|---|
CN109362222B (zh) | 2021-03-19 |
BR112018015419A2 (pt) | 2018-12-18 |
US20200040001A1 (en) | 2020-02-06 |
US10647724B2 (en) | 2020-05-12 |
US11014936B2 (en) | 2021-05-25 |
CA3012078C (en) | 2024-01-30 |
EP3411034A1 (en) | 2018-12-12 |
JP6905539B2 (ja) | 2021-07-21 |
CN109362222A (zh) | 2019-02-19 |
BR112018015419B1 (pt) | 2024-01-30 |
EP3411034B1 (en) | 2020-11-25 |
US20200048250A1 (en) | 2020-02-13 |
KR102479822B1 (ko) | 2022-12-21 |
WO2017136688A1 (en) | 2017-08-10 |
RU2734501C2 (ru) | 2020-10-19 |
ES2842579T3 (es) | 2021-07-14 |
IL260789B (en) | 2021-03-25 |
CN113004273A (zh) | 2021-06-22 |
CA3012078A1 (en) | 2017-08-10 |
JP2019504890A (ja) | 2019-02-21 |
RU2018128318A (ru) | 2020-03-05 |
ZA201805573B (en) | 2020-12-23 |
US20210253592A1 (en) | 2021-08-19 |
RU2018128318A3 (es) | 2020-04-02 |
EP3411034A4 (en) | 2019-08-28 |
AU2017213614A1 (en) | 2018-08-09 |
US20240043442A1 (en) | 2024-02-08 |
AU2017213614B2 (en) | 2022-09-01 |
DK3411034T3 (da) | 2021-01-11 |
KR20180104161A (ko) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018009496A (es) | Degradadores selectivos del receptor de estrogeno y sus usos. | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
GEP20207161B (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
PH12016502607A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
PH12016500967A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
TN2016000472A1 (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer. | |
MX2017013360A (es) | Métodos para tratar el cáncer. | |
PH12018500829A1 (en) | Novel heterocyclic antiestrogens | |
MX2018009913A (es) | Aglutinantes max como moduladores myc y sus usos. | |
MX2016016419A (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE | |
WO2017095950A3 (en) | Compounds for treating proliferative diseases | |
MX2017017119A (es) | Formulacion de alta concentracion. | |
MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
EP3612161A4 (en) | FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS, AND USES THEREOF FOR TREATMENT OF CANCER | |
EA201992045A1 (ru) | Ингибиторы pd-1/pd-l1 | |
WO2015024000A3 (en) | Mitochondrially-targeted electrophilic compounds for cancer treatment |